SCHEMBL2094067

SCHEMBL2094067

CO[CH]c1noc(-c2ccccc2)n1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H4 Q96RI1 3/20 0.52
S1PR1 P21453 1/20 0.51
CASP3 P42574 4/20 0.51
SENP7 Q9BQF6 4/20 0.51
SENP8 Q96LD8 3/20 0.51
SENP6 Q9GZR1 3/20 0.51
NPC1 O15118 9/20 0.50
RAB9A P51151 9/20 0.50
SMN1; SMN2 Q16637 9/20 0.50
ALDH1A1 P00352 3/20 0.50
TP53 P04637 3/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
NFKB1 P19838 3/20 0.47
NFKB2 Q00653 3/20 0.47
RELA Q04206 3/20 0.47
MAPT P10636 4/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
KDM4E B2RXH2 2/20 0.46
TDP1 Q9NUW8 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14562709 0.77 NR1H4 (0.57) NR1H4CASP3SENP7SENP8SENP6
SCHEMBL22621631 0.73 NR1H4 (0.60) NR1H4S1PR1NPC1RAB9ASMN1; SMN2
SCHEMBL806849 0.70 ACHE (0.66) NR1H4S1PR1CASP3SENP7SENP6
SCHEMBL13962652 0.69 NR1H4 (0.57) NR1H4S1PR1CASP3SENP7SENP6
SCHEMBL2089121 0.69 RAB9A (0.58) NR1H4S1PR1CASP3SENP7SENP8
SCHEMBL2094070 0.69 NOTUM (0.62) NR1H4S1PR1NPC1RAB9ASMN1; SMN2
SCHEMBL513442 0.69 NR1H4 (0.47) NR1H4S1PR1CASP3SENP7SENP8
SCHEMBL1473020 0.69 NR1H4 (1.00) NR1H4S1PR1CASP3SENP7SENP8
SCHEMBL3614849 0.68 HDAC1 (0.44) NR1H4CASP3SENP7SENP8SENP6
SCHEMBL6697420 0.68 NR1H4 (1.00) NR1H4S1PR1NPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8163753-B2 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-04-24 US disclosed
EP-1678185-B1 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMA CO LTD (JP) 2008-10-08 EP disclosed
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis OTSUKA PHAMACEUTICAL CO., LTD. (JP) 2008-05-22 US disclosed
EP-1678185-A1 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-07-12 EP disclosed
WO-2005042542-A1 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-05-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis NR2C2, NR0B2, NR4A2 NR1H4 446/4885S1PR1 1852/4885CASP3 2032/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.